Q1 2025 Management View Co-CEO Bob Duggan highlighted significant progress with ivonescimab, Summit Therapeutics' lead investigational asset, emphasizing its potential impact on unmet medical needs.

Race Oncology has begun dosing patients in a Phase 1 clinical trial assessing RC220 in solid tumours ... Read More The post ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

Cash Position: GeoVax reported cash balances of $7.4 million at March 31, 2025, as compared to $5.5 million at December 31, 2024. Summarized financial information is attached. Further information is ...

"In the phase 3 randomized clinical trial, once-daily oral ivarmacitinib (4 or 8 mg) led to significant improvements in the ...

A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following ...

AVB-101 Biomarker Data Readout Expected in 2026 Clinical Milestone Shared at AFTD Annual Caregiver Conference AviadoBio, a pioneering gene therapy company dedicated to developing and delivering ...

Avacopan has been shown to work well in a real-world setting in a much broader group of people with vasculitis than was studied in the phase 3 trial that led to its approval.

Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Obesity Program- enobosarm is a next generation drug that makes weight reduction by GLP-1 RA more tissue selective for fat ...